ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2025
Prevalence and awareness of hepatitis B and hepatitis C and vaccine-induced immunity to hepatitis B: Findings from the Canadian Health Measure Survey, 2016-2019.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- National hepatitis B and C estimates for 2021: Measuring Canada's progress towards eliminating viral hepatitis as a public health concern.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are sexually transmitted and blood-borne infections that Canada is committed to eliminate as public health concerns. Accurate epidemiological estimates require cross-sectional data as input. The objective of this study was to estimate the prevalence of present HBV infection (hepatitis B surface antigen-positive) and proportion aware of their infection, the vaccine-induced HBV immunity, the prevalence of HCV antibodies (anti-HCV-positive), the prevalence of present HCV infection (RNA-positive) and proportion aware of their infection, in the household population in Canada. These outcomes were also examined by selected demographic characteristics. Methods: A total of 7,543 sera from participants of the Canadian Health Measure Survey (CHMS) cycles 5 (2016-2017) and 6 (2018-2019) who consented to participate in Statistics Canada's Biobank were tested to determine their HBV and HCV status. Information from the CHMS household questionnaire was linked to the laboratory results to report on sociodemographic characteristics and awareness of infection. Results: The stored serum combined response rate for this study, which takes into account households' and respondents' participation in the CHMS and the Biobank was 42.8%. The estimated prevalence of present HBV infection among people aged 14 to 79 years was 0.4% (95% CI: 0.1%-0.7%), of whom 49.0% (95% CI: 15.4%-82.6%) were aware of their infection. An estimated 39.0% (95% CI: 37.0%-41.0%) of people aged 11 to 79 years had laboratory evidence of vaccine-induced HBV immunity. An estimated 0.5% (95% CI: 0.2%-0.8%) of people aged 14 to 79 years were positive for anti-HCV, and 0.2% (95% CI: 0.0%-0.3%) had a present infection (RNA-positive), of whom 51.2% (95% CI: 9.5%-92.9%) were aware of their infection. Conclusion: Cross-sectional data using nationally representative surveys are essential in assessing the burden of viral hepatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.